Kalaris Therapeutics, Inc.

Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.

KLRS | NDAQ

Overview

Corporate Details

ISIN(s):: US0198181036
LEI:
Country:: United States of America
Address:: 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
Website:: https://kalaristx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate is TH103, a fully humanized, recombinant fusion protein designed as a next-generation anti-VEGF agent for intravitreal delivery. Co-developed by Dr. Napoleone Ferrara, known for his work on Avastin and Lucentis, TH103 acts as a soluble decoy receptor. A key feature is its high affinity for heparan sulfate proteoglycans (HSPG), which may act as a molecular anchor to extend its intraocular retention. This mechanism aims to reduce the frequency of injections for patients with neovascular retinal diseases, such as age-related macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kalaris Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Calliditas Therapeutics Develops and commercializes novel treatments for rare renal and hepatic diseases like IgA nephropathy.	Sweden	CALTX
CALTH. Inc Develops AI-powered rapid diagnostic solutions for point-of-care and self-testing.	South Korea	402420
CAMBRIDGE NUTRITIONAL SCIENCES PLC Develops and manufactures diagnostic tests for food sensitivity and gut health.	United Kingdom	CNSL
Camp4 Therapeutics Corp Developing RNA-based therapies to upregulate genes for rare metabolic and CNS disorders.	United States of America	CAMP
Camurus Develops long-acting medicines for severe chronic diseases using advanced drug delivery.	Sweden	CAMX
CanBas Co.,Ltd. Clinical-stage biopharma developing novel cancer drugs aiming for fewer side effects.	Japan	4575
Candel Therapeutics, Inc. Developing off-the-shelf viral immunotherapies to help the immune system fight solid tumors.	United States of America	CADL
Can-Fite BioPharma Ltd. Develops oral small-molecule drugs targeting A3AR for oncology and inflammatory diseases.	Israel	CANF
Can-Fite BioPharma Ltd. Clinical-stage biopharma developing oral drugs for cancer, inflammatory, liver & metabolic diseases.	United States of America	CANF
Cannovum Cannabis AG Importer & producer of medical cannabis, expanding into recreational cultivation infrastructure.	Germany	27N0